Black Diamond Therapeutics/BDTX

$5.29

-0.19%
-
1D1W1MYTD1YMAX

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Ticker

BDTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Velleca

Employees

54

Headquarters

Cambridge, United States

BDTX Metrics

BasicAdvanced
$294.79M
Market cap
-
P/E ratio
-$1.92
EPS
2.55
Beta
-
Dividend rate
$294.79M
2.55187
$6.85
$1.43
607.28K
6.822
-52.37%
-70.94%
-58.91%
2.522
2.525
23.36%

What the Analysts think about BDTX

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
141.97% upside
High $16.00
Low $10.00
$5.29
Current price
$12.80
Average price target

BDTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-19.4M
-15.65%
Profit margin
0%
-

BDTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 27.04%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.57
-$0.52
-$0.45
-$0.34
-
Expected
-$0.61
-$0.54
-$0.49
-$0.47
-$0.44
Surprise
-6.17%
-2.95%
-7.5%
-27.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Black Diamond Therapeutics stock?

Black Diamond Therapeutics (BDTX) has a market cap of $274.1M as of April 20, 2024.

What is the P/E ratio for Black Diamond Therapeutics stock?

The price to earnings (P/E) ratio for Black Diamond Therapeutics (BDTX) stock is 0 as of April 20, 2024.

Does Black Diamond Therapeutics stock pay dividends?

No, Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Black Diamond Therapeutics dividend payment date?

Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Black Diamond Therapeutics?

Black Diamond Therapeutics (BDTX) has a beta rating of 2.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Black Diamond Therapeutics stock price target?

The target price for Black Diamond Therapeutics (BDTX) stock is $12.8, which is 143.35% above the current price of $5.26. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Black Diamond Therapeutics stock

Buy or sell Black Diamond Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing